Summary of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings as of Jun 27, 2018

June 27, 2018 - By Ricky Cave

Big Money Sentiment decreased to 1.19 in Q1 2018. It has change of 0.01, from 2017Q4’s 1.2. The ratio dropped due to Aerie Pharmaceuticals, Inc. positioning: 18 sold and 46 reduced. 17 funds took holdings and 59 increased holdings. Investors holded 34.86 million in 2017Q4 but now own 39.43 million shares or 13.11% more.
State Board Of Administration Of Florida Retirement Systems invested in 0% or 17,741 shs. Swiss Bancorp has invested 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 31,792 are held by Rhumbline Advisers. Voya Inv Mgmt Ltd Com reported 455,450 shs. Northern reported 433,548 shs or 0.01% of all its holdings. Alyeska Investment Gp Ltd Partnership holds 301,103 shs. Harvey Management invested in 0.48% or 23,519 shs. Perigon Wealth Mgmt Ltd owns 1,098 shs. Atwood Palmer Incorporated invested in 200 shs. The Massachusetts-based State Street Corp has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Manufacturers Life Insurance The reported 25,409 shs stake. Jpmorgan Chase accumulated 7,619 shs. Teacher Retirement System Of Texas invested in 0% or 6,903 shs. 5,766 are held by United Services Automobile Association. C Wide Gp A S holds 0.06% or 72,739 shs in its capital.

Aerie Pharmaceuticals, Inc. had 4 sales and 2 insider buys since May 21, 2018. This’s net activity of $13.13 million. The insider Cagle Gerald D. bought $50,245. On Wednesday, June 6 Shares for $9.34M were sold by ANIDO VICENTE JR.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 2, 2018 according to StockzIntelligence Inc Aerie Pharma has 10 analyst reports. On Wednesday, May 9 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, May 8 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald. On Wednesday, February 28 the company was maintained by Cantor Fitzgerald. On Tuesday, January 2 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus. The stock rating was maintained by Mizuho with “Buy” on Wednesday, May 9. On Thursday, March 1 the firm earned “Buy” rating by H.C. Wainwright. In Wednesday, January 24 report Canaccord Genuity maintained it with “Buy” rating and $86.0 target. On Thursday, March 29 the firm has “Buy” rating given by Mizuho. On Friday, February 16 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by H.C. Wainwright. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

Ticker’s shares touched $68.5 during the last trading session after 0.66% change.Aerie Pharmaceuticals, Inc. has volume of 105,247 shares. Since June 27, 2017 AERI has declined 8.48% and is downtrending. The stock underperformed the S&P 500 by 21.05%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.71 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: which released on June 02, 2018 “Aerie Pharmaceuticals to Present at the NASDAQ 38”, also on June 09, 2018 published “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares”, the next is “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel” on June 18, 2018. has article titled “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.